Edward Nirenberg on Nostr: Clesrovimab is also being assessed in a phase 3 study comparing it to palivizumab in ...

Clesrovimab is also being assessed in a phase 3 study comparing it to palivizumab in infants at increased risk for severe RSV. At the second season, the trial becomes open label with the option to receive clesrovimab. Efficacy was comparable for palivizumab and clesrovimab.